{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:52:04Z","timestamp":1794491524347,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Trial sponsored by Small Pharma LTD"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Major depressive disorder (MDD) is a leading cause of disability worldwide, yet many patients have inadequate responses to current treatments. Dimethyltryptamine (DMT), a serotonergic psychedelic with rapid onset and short duration, shows promise as a potential antidepressant (AD), although clinical evidence in MDD remains limited. We conducted a phase IIa, double-blind, placebo-controlled, randomized clinical trial to evaluate the efficacy and safety of intravenous DMT (SPL026; DMT fumarate) in adults with moderate-to-severe MDD. Participants received a single 21.5-mg dose of DMT or placebo infused over 10\u2009min, along with supportive psychotherapeutic support, followed by a 2-week assessment. A subsequent open-label phase offered all participants a second DMT dose. The primary outcome was the change in Montgomery\u2013\u00c5sberg Depression Rating Scale (MADRS) at 2 weeks. Secondary outcomes included response (\u226550% reduction in MADRS score) and remission (MADRS\u2009\u2264\u200910). A total of 34 participants were randomized, 17 to placebo\u2013active and 17 to active\u2013active. At 2 weeks, the DMT group showed a significantly greater reduction in MADRS score than placebo (mean difference\u2009=\u2009\u22127.35; 95% CI\u2009=\u2009\u221213.62 to \u22121.08;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.023). In the open-label phase, AD effects persisted up to 3 months, with no significant differences between those who received one versus two doses. Adverse events were mostly mild to moderate, commonly infusion site pain, nausea and transient anxiety. No serious adverse events occurred. A single dose of DMT with psychotherapeutic support produced a rapid, significant reduction in depressive symptoms, sustained up to 3 months. The treatment was well-tolerated and safe. ClinicalTrials.gov registration:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04673383\" ext-link-type=\"uri\">NCT04673383<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-025-04154-z","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:02:53Z","timestamp":1771257773000},"page":"591-598","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7022-6211","authenticated-orcid":false,"given":"David","family":"Erritzoe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2565-4628","authenticated-orcid":false,"given":"Tommaso","family":"Barba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffanie","family":"Benway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelah","family":"Joel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Good","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Layzell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6557-0503","authenticated-orcid":false,"given":"Michelle Baker","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashleigh","family":"Murphy-Beiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Boyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Topping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2281-377X","authenticated-orcid":false,"given":"Christopher","family":"Timmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1286-1401","authenticated-orcid":false,"given":"David","family":"Nutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6062-7150","authenticated-orcid":false,"given":"Robin","family":"Carhart-Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Routledge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9554-573X","authenticated-orcid":false,"given":"Ellen","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"4154_CR1","doi-asserted-by":"crossref","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1789\u20131858 (2018).","DOI":"10.1016\/S0140-6736(18)32279-7"},{"key":"4154_CR2","first-page":"1517","volume":"317","author":"MJ Friedrich","year":"2017","unstructured":"Friedrich, M. J. Depression is the leading cause of disability around the world. JAMA 317, 1517\u20131517 (2017).","journal-title":"JAMA"},{"key":"4154_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4068\/cmj.2018.54.2.101","volume":"54","author":"SM Wang","year":"2018","unstructured":"Wang, S. M. et al. Addressing the side effects of contemporary antidepressant drugs: a comprehensive review. Chonnam Med. J. 54, 101\u2013112 (2018).","journal-title":"Chonnam Med. J."},{"key":"4154_CR4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/13651501.2020.1779308","volume":"24","author":"F Cosci","year":"2020","unstructured":"Cosci, F., Mansueto, G. & Fava, G. A. Relapse prevention in recurrent major depressive disorder. A comparison of different treatment options based on clinical experience and a critical review of the literature. Int. J. Psychiatry Clin. Pract. 24, 341\u2013348 (2020).","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"4154_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cell.2020.03.020","volume":"181","author":"D Nutt","year":"2020","unstructured":"Nutt, D., Erritzoe, D. & Carhart-Harris, R. Psychedelic psychiatry\u2019s brave new world. Cell 181, 24\u201328 (2020).","journal-title":"Cell"},{"key":"4154_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102799","volume":"76","author":"D Erritzoe","year":"2024","unstructured":"Erritzoe, D. et al. Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial. EClinicalMedicine 76, 102799 (2024).","journal-title":"EClinicalMedicine"},{"key":"4154_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078084","volume":"385","author":"AM Metaxa","year":"2024","unstructured":"Metaxa, A. M. & Clarke, M. Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. BMJ 385, e078084 (2024).","journal-title":"BMJ"},{"key":"4154_CR8","unstructured":"Nutt, D. J. & Thurgur, H. (eds). International Review of Neurobiology, pp. 271\u2013304 (Academic Press, 2025)."},{"key":"4154_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.116337","volume":"344","author":"D Swieczkowski","year":"2025","unstructured":"Swieczkowski, D. et al. Efficacy and safety of psilocybin in the treatment of major depressive disorder (MDD): a dose\u2013response network meta-analysis of randomized placebo-controlled clinical trials. Psychiatry Res. 344, 116337 (2025).","journal-title":"Psychiatry Res."},{"key":"4154_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1305796","volume":"14","author":"E James","year":"2024","unstructured":"James, E. et al. Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial. Front. Psychiatry 14, 1305796 (2024).","journal-title":"Front. Psychiatry"},{"key":"4154_CR11","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","volume":"391","author":"A Cipriani","year":"2018","unstructured":"Cipriani, A. et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 391, 1357\u20131366 (2018).","journal-title":"Lancet"},{"key":"4154_CR12","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s43440-020-00097-z","volume":"72","author":"J Kryst","year":"2020","unstructured":"Kryst, J. et al. Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials. Pharmacol. Rep. 72, 543\u2013562 (2020).","journal-title":"Pharmacol. Rep."},{"key":"4154_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.brainresbull.2016.04.016","volume":"126","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro, T. M. & Gatch, M. B. Neuropharmacology of N,N-dimethyltryptamine. Brain Res. Bull. 126, 74\u201388 (2016).","journal-title":"Brain Res. Bull."},{"key":"4154_CR14","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1177\/0269881117725915","volume":"31","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris, R. L. & Nutt, D. J. Serotonin and brain function: a tale of two receptors. J. Psychopharmacol. 31, 1091\u20131120 (2017).","journal-title":"J. Psychopharmacol."},{"key":"4154_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-53363-y","volume":"14","author":"C Timmermann","year":"2024","unstructured":"Timmermann, C. et al. Effects of DMT on mental health outcomes in healthy volunteers. Sci. Rep. 14, 3097 (2024).","journal-title":"Sci. Rep."},{"key":"4154_CR16","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1038\/s41386-022-01344-y","volume":"47","author":"DC D\u2019Souza","year":"2022","unstructured":"D\u2019Souza, D. C. et al. Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. Neuropsychopharmacology 47, 1854\u20131862 (2022).","journal-title":"Neuropsychopharmacology"},{"key":"4154_CR17","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s41386-024-02041-8","volume":"50","author":"L Erne","year":"2025","unstructured":"Erne, L. et al. Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants. Neuropsychopharmacology 50, 1008\u20131016 (2025).","journal-title":"Neuropsychopharmacology"},{"key":"4154_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02477-4","volume":"13","author":"SB Vogt","year":"2023","unstructured":"Vogt, S. B. et al. Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants. Transl. Psychiatry 13, 172 (2023).","journal-title":"Transl. Psychiatry"},{"key":"4154_CR19","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41386-025-02091-6","volume":"50","author":"M Falchi-Carvalho","year":"2025","unstructured":"Falchi-Carvalho, M. et al. Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression. Neuropsychopharmacology 50, 895\u2013903 (2025).","journal-title":"Neuropsychopharmacology"},{"key":"4154_CR20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s13318-023-00822-y","volume":"48","author":"M Good","year":"2023","unstructured":"Good, M. et al. Pharmacokinetics of N,N-dimethyltryptamine in humans. Eur. J. Drug Metab. Pharmacokinet. 48, 311\u2013327 (2023).","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"4154_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.788155","volume":"12","author":"R Murphy","year":"2021","unstructured":"Murphy, R. et al. Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression. Front. Pharmacol. 12, 788155 (2021).","journal-title":"Front. Pharmacol."},{"key":"4154_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/7854_2023_451","volume":"66","author":"DJ Nutt","year":"2024","unstructured":"Nutt, D. J. et al. Psilocybin and other classic psychedelics in depression. Curr. Top. Behav. Neurosci. 66, 149\u2013174 (2024).","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"4154_CR23","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","volume":"330","author":"CL Raison","year":"2023","unstructured":"Raison, C. L. et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA 330, 843\u2013853 (2023).","journal-title":"JAMA"},{"key":"4154_CR24","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin, G. M. et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N. Engl. J. Med. 387, 1637\u20131648 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4154_CR25","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly, C. et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 23, 3170\u20133182 (2018).","journal-title":"Cell Rep."},{"key":"4154_CR26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2218949120","volume":"120","author":"C Timmermann","year":"2023","unstructured":"Timmermann, C. et al. Human brain effects of DMT assessed via EEG-fMRI. Proc. Natl Acad. Sci. USA 120, e2218949120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4154_CR27","volume":"9","author":"A Alamia","year":"2020","unstructured":"Alamia, A. et al. DMT alters cortical travelling waves. eLife 9, 12 (2020).","journal-title":"eLife"},{"key":"4154_CR28","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1017\/S0033291723003653","volume":"54","author":"B Szigeti","year":"2024","unstructured":"Szigeti, B. et al. Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression. Psychol. Med. 54, 1717\u20131724 (2024).","journal-title":"Psychol. Med."},{"key":"4154_CR29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S2215-0366(23)00363-2","volume":"11","author":"G Gr\u00fcnder","year":"2024","unstructured":"Gr\u00fcnder, G. et al. Treatment with psychedelics is psychotherapy: beyond reductionism. Lancet Psychiatry 11, 231\u2013236 (2024).","journal-title":"Lancet Psychiatry"},{"key":"4154_CR30","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1017\/S0033291718001356","volume":"49","author":"F Palhano-Fontes","year":"2019","unstructured":"Palhano-Fontes, F. et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol. Med. 49, 655\u2013663 (2019).","journal-title":"Psychol. Med."},{"key":"4154_CR31","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery, S. A. & Asberg, M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134, 382\u2013389 (1979).","journal-title":"Br. J. Psychiatry"},{"key":"4154_CR32","doi-asserted-by":"crossref","unstructured":"Beck, A. T., Steer, R. A. & Brown, G. K. Beck Depression Inventory (Psychological Corporation, 1996).","DOI":"10.1037\/t00742-000"},{"key":"4154_CR33","first-page":"145","volume":"5","author":"CD Spielberger","year":"1971","unstructured":"Spielberger, C. D. et al. The State-Trait Anxiety Inventory. Interam. J. Psychol. 5, 145\u2013158 (1971).","journal-title":"Interam. J. Psychol."},{"key":"4154_CR34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1192\/bjp.bp.106.032532","volume":"192","author":"JB Williams","year":"2008","unstructured":"Williams, J. B. & Kobak, K. A. Development and reliability of a structured interview guide for the Montgomery\u2013\u00c5sberg Depression Rating Scale (SIGMA). Br. J. Psychiatry 192, 52\u201358 (2008).","journal-title":"Br. J. Psychiatry"},{"key":"4154_CR35","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1177\/0269881115609019","volume":"29","author":"FS Barrett","year":"2015","unstructured":"Barrett, F. S., Johnson, M. W. & Griffiths, R. R. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J. Psychopharmacol. 29, 1182\u20131190 (2015).","journal-title":"J. Psychopharmacol."},{"key":"4154_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2016.00269","volume":"10","author":"MM Nour","year":"2016","unstructured":"Nour, M. M. et al. Ego-dissolution and psychedelics: validation of the Ego-Dissolution Inventory (EDI). Front. Hum. Neurosci. 10, 269 (2016).","journal-title":"Front. Hum. Neurosci."},{"key":"4154_CR37","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1177\/0269881119855974","volume":"33","author":"L Roseman","year":"2019","unstructured":"Roseman, L. et al. Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory. J. Psychopharmacol. 33, 1076\u20131087 (2019).","journal-title":"J. Psychopharmacol."},{"key":"4154_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012412","volume":"5","author":"E Studerus","year":"2010","unstructured":"Studerus, E., Gamma, A. & Vollenweider, F. X. Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS ONE 5, e12412 (2010).","journal-title":"PLoS ONE"},{"key":"4154_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/02698811211066709","volume":"36","author":"JM Peill","year":"2022","unstructured":"Peill, J. M. et al. Validation of the psychological insight scale: a new scale to assess psychological insight following a psychedelic experience. J. Psychopharmacol. 36, 31\u201345 (2022).","journal-title":"J. Psychopharmacol."},{"key":"4154_CR40","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1177\/0269881116678781","volume":"30","author":"FS Barrett","year":"2016","unstructured":"Barrett, F. S. et al. The Challenging Experience Questionnaire: characterization of challenging experiences with psilocybin mushrooms. J. Psychopharmacol. 30, 1279\u20131295 (2016).","journal-title":"J. Psychopharmacol."},{"key":"4154_CR41","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1017\/S0033291724002204","volume":"54","author":"M Angyus","year":"2024","unstructured":"Angyus, M. et al. Validation of the imperial psychedelic predictor scale. Psychol. Med. 54, 3539\u20133547 (2024).","journal-title":"Psychol. Med."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04154-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04154-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04154-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T18:02:53Z","timestamp":1771783373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04154-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4154"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04154-z","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.E. serves as a paid scientific advisor for Aya Biosciences, Lophora Aps, Clerkenwell Health and Mindstate Design Lab. D.N. has no current affiliations with companies developing psychedelic treatments for depression, although he previously advised COMPASS Pathways. He currently advises Algernon Pharmaceuticals on the nonpsychedelic application of DMT for stroke and Neural Therapeutics on mescaline research. G.C. was employed by Small Pharma at the time of the trial (fully seconded to HMR). C.R. and P.R. were employed by Small Pharma and held shares in the company at the time of the trial. R.C.-H. is a scientific advisor to TRYP Therapeutics, MindState and Otsuka. T. Benway was employed by Small Pharma during the trial and is a shareholder; she is now employed by GH Research. E.J., M.L., Z.J. and M.G. were employed by Small Pharma and are now employed by Cybin UK\/IRL, trading as Helus\/CybinIRL, and are option holders\/shareholders in Cybin. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}